Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
395.92
+8.15 (2.10%)
At close: Aug 13, 2025, 4:00 PM
396.00
+0.08 (0.02%)
After-hours: Aug 13, 2025, 7:58 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 21 professional analysts, the 12-month price target for Vertex Pharmaceuticals stock ranges from a low of $405 to a high of $575. The average analyst price target of $496.76 forecasts a 25.47% increase in the stock price over the next year.
Price Target: $496.76 (+25.47%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 9 | 8 | 8 |
| Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Hold | 10 | 10 | 11 | 11 | 11 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 25 | 26 | 27 | 26 | 25 | 24 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $424 → $411 | Hold | Maintains | $424 → $411 | +3.81% | Aug 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $558 → $546 | Strong Buy | Maintains | $558 → $546 | +37.91% | Aug 6, 2025 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $460 | Hold → Buy | Upgrades | $460 | +16.19% | Aug 6, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $520 → $490 | Strong Buy | Maintains | $520 → $490 | +23.76% | Aug 5, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $442 → $438 | Hold | Maintains | $442 → $438 | +10.63% | Aug 5, 2025 |
Financial Forecast
Revenue This Year
12.17B
from 11.02B
Increased by 10.40%
Revenue Next Year
13.46B
from 12.17B
Increased by 10.63%
EPS This Year
18.30
from -2.08
EPS Next Year
21.10
from 18.30
Increased by 15.30%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 12.9B | 15.7B | 17.7B | |
| Avg | 12.2B | 13.5B | 14.7B | |
| Low | 11.5B | 11.7B | 11.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 16.7% | 29.1% | 31.6% | |
| Avg | 10.4% | 10.6% | 9.4% | |
| Low | 4.5% | -3.8% | -13.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 19.73 | 28.05 | 33.75 | |
| Avg | 18.30 | 21.10 | 23.41 | |
| Low | 16.56 | 17.36 | 18.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | - | 53.2% | 59.9% | |
| Avg | - | 15.3% | 10.9% | |
| Low | - | -5.2% | -11.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.